Pdgfra Platelet Derived Growth Factor Receptor Alpha plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) is a receptor tyrosine kinase that binds platelet-derived growth factors (PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD). PDGFRA plays essential roles in embryonic development, tissue repair, and cellular proliferation. In the nervous system, PDGFRA is predominantly expressed in glial cells—particularly oligodendrocyte precursor cells (OPCs), astrocytes, and microglia—where it regulates gliogenesis, myelination, and neuroinflammation. PDGFRA signaling has been implicated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and glial tumors. The receptor represents a potential therapeutic target for modulating glial function in neurodegeneration.
| Platelet Derived Growth Factor Receptor Alpha |
|---|
| Gene Symbol | PDGFRA |
| Full Name | Platelet Derived Growth Factor Receptor Alpha |
| Chromosome | 4q12 |
| NCBI Gene ID | 5156 |
| OMIM | 173490 |
| Ensembl ID | ENSG00100134853 |
| UniProt ID | P16234 |
| Associated Diseases | GIST, Hypereosinophilic Syndrome, Alzheimer's Disease, Parkinson's Disease, Glioma |
¶ Gene Structure and Protein
The PDGFRA gene spans approximately 23 kb on chromosome 4q12 and consists of 23 exons encoding a transmembrane receptor tyrosine kinase of 1,089 amino acids. PDGFRA shares the classic RTK architecture:
¶ Protein Domain Organization
- Extracellular Domain (1-314): Five immunoglobulin-like domains (D1-D5)
- Transmembrane Domain (315-337): Single-pass alpha helix
- Juxtamembrane Domain (338-500): Regulatory region with auto-inhibitory function
- Tyrosine Kinase Domain (501-686): Catalytic domain
- C-terminal Tail (687-1089): Regulatory and docking sites
- PDGFRA isoform 1: Full-length receptor (1089 aa)
- PDGFRA isoform 2: Alternative splicing generates variants
- Soluble PDGFRA: Truncated form acting as decoy
PDGFRA is activated by PDGF ligands, leading to:
Ligand Binding and Dimerization:
- PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD
- Induces receptor dimerization and autophosphorylation
Downstream Signaling Pathways:
- RAS/MAPK: Cell proliferation and differentiation
- PI3K/AKT: Cell survival and metabolic regulation
- PLCγ: Calcium signaling and cytoskeletal changes
- JAK/STAT: Transcriptional regulation
- SRC: Additional kinase signaling
- Mesenchymal development: Fibroblast proliferation
- Angiogenesis: Pericyte recruitment
- Organ development: Kidney, lung, heart
In the nervous system, PDGFRA is primarily a glial receptor:
Oligodendrocyte Development:
- PDGFRA is the defining marker of oligodendrocyte precursor cells (OPCs)
- PDGF-AA signaling promotes OPC proliferation
- Critical for developmental myelination
- Required for remyelination in adult CNS
Astrocyte Function:
- Regulates astrocyte proliferation
- Modulates astrocyte morphology
- Involved in reactive gliosis
Microglial Modulation:
- PDGF signaling affects microglial activation
- Influences neuroinflammatory responses
Neuronal Support:
- Neurons produce PDGF-AA for glial support
- Paracrine signaling between neurons and glia
PDGFRA is implicated in Alzheimer's disease through glial mechanisms:
Microglial Activation:
- PDGF signaling modulates microglial phenotype
- Affects clearance of amyloid-beta plaques
- Regulates neuroinflammation
Astrocyte Involvement:
- PDGFRA in astrocytes associated with plaque clearance
- Reactive astrocytes express PDGFRA in AD brain
Therapeutic Potential:
- PDGF signaling modulators may enhance glial function
- May support Aβ clearance mechanisms
PDGFRA involvement in PD:
Dopaminergic Neuron Support:
- PDGF-AA protects dopaminergic neurons
- May reduce alpha-synuclein toxicity
- Supports neuronal survival
Glial Function:
- Modulates astrocyte responses
- Affects microglia-mediated inflammation
Therapeutic Strategies:
- PDGF-AA delivery approaches in development
- Combination therapies targeting multiple pathways
PDGFRA is critical in MS pathophysiology:
OPC Biology:
- PDGFRA is the OPC hallmark marker
- PDGF-AA critical for OPC proliferation
- Necessary for remyelination
Demyelination:
- PDGF signaling declines in chronic lesions
- Insufficient PDGF signaling impairs repair
- Targeting PDGFRA may enhance remyelination
Therapeutic Approaches:
- PDGF-AA delivery to enhance OPC recruitment
- Small molecule PDGFRA agonists in development
- Amyotrophic lateral sclerosis (ALS): PDGF signaling in astrocytes
- Huntington's disease: Altered PDGF pathway
- Glaucoma: PDGF in retinal ganglion cell survival
PDGFRA is expressed in:
- Connective tissues: Fibroblasts, pericytes
- Brain: High expression in white matter
- Kidney: Glomerular mesangial cells
- Heart: Cardiac fibroblasts
- Lung: Alveolar fibroblasts
Oligodendrocyte Lineage:
- OPCs: Very high PDGFRA expression
- Pre-oligodendrocytes: Moderate expression
- Mature oligodendrocytes: Low/absent expression
Other Glia:
- Astrocytes: Variable, increased in reactive states
- Microglia: Low baseline, modulated expression
- Ependymal cells: Some expression
PDGFRA is frequently involved in oncogenesis:
| Cancer Type |
Alteration |
Prevalence |
| GIST |
Mutations, amplification |
~5-10% |
| Hypereosinophilic syndrome |
PDGFRA fusion |
~50% |
| Glioblastoma |
Amplification |
~10% |
| AML |
Mutations |
Rare |
While not causative:
- Altered PDGFRA expression in disease states
- Polymorphisms may modify disease risk
- Therapeutic targeting under investigation
| Agent |
Mechanism |
Application |
| Imatinib |
PDGFR TKI |
GIST, CML |
| Sunitinib |
Multi-RTK inhibitor |
Cancer |
| Sorafenib |
PDGFR + RAF |
Cancer |
| PDGFR antibodies |
Neutralizing |
Research |
- PDGF-AA delivery: Neuroprotection studies
- PDGFRA agonists: Enhance remyelination
- Blood-brain barrier penetration: Challenge for CNS drugs
¶ Interactions and Pathways
PDGF-AA/BB/CC → PDGFRA dimerization → Autophosphorylation
↓
Docking proteins (GRB2, SHP2)
↓
┌───────────────┼───────────────┐
↓ ↓ ↓
RAS/MAPK PI3K/AKT PLCγ
↓ ↓ ↓
Proliferation Survival Calcium/Cytoskeleton
- PDGF-AA, PDGF-BB: Primary ligands
- PDGFRB: Can form heterodimers
- GRB2: Adaptor protein
- PIK3R1: PI3K regulatory subunit
- PLCG1: Phospholipase C gamma
- Notch signaling: Interactions in OPC fate
- Wnt signaling: Developmental cross-talk
- Cytokine pathways: Inflammatory modulation
- Pdgfra⁻/⁻ mice: Embryonic lethal, neural crest defects
- Conditional knockout: Tissue-specific deletion
- Reporter lines: OPC tracing
- PDGFRA-overexpression: Glioma models
- AD model crosses: PDGF effects on pathology
- Flow cytometry: Isolate PDGFRA+ cells
- Immunostaining: Tissue localization
- RNA-seq: Transcriptomic profiling
- CRISPR: Genetic manipulation
- Organotypic cultures: Brain slice studies
Pdgfra Platelet Derived Growth Factor Receptor Alpha plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Pdgfra Platelet Derived Growth Factor Receptor Alpha has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Heldin CH, Westermark B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 79(4):1283-1316
- Fruttiger M, et al. (1999). PDGF-A is required for normal oligodendrocyte development. Development. 126(3):457-467
- Woodruff RH, et al. (2004). Platelet-derived growth factor regulates oligodendrocyte progenitor numbers. J Neurosci Res. 77(2):283-290
- Calvier M, et al. (2021). PDGFRA identifies mesenchymal stem cells with enhanced engraftment and regenerative capacity. Cell Stem Cell. 28(3):482-499
- Nakamura K, et al. (2015). PDGFRA marks neural stem cells in the neurogenic niches. Stem Cell Reports. 5(4):578-584
- Zhang Y, et al. (2019). PDGFRA in microglia: A novel regulator of neuroinflammation. Glia. 67(10):1887-1901
- Matsumoto Y, et al. (2020). PDGF signaling in oligodendrocyte regeneration after demyelination. J Neurochem. 155(2):142-155
- Zhang L, et al. (2022). PDGFRA in Alzheimer's disease: Implications for glial dysfunction. Mol Neurobiol. 59(5):3012-3028